By Barbara Obstoj-Cardwell. Editor
Events in the pharma sector hitting the headlines last week included a hitch for Merck & Co’s Keytruda, mixed results for Cara Therapeutics’ pain drug candidate CR848, Celgene’s deal with China’s BeiGene and an overview on the sluggish first-half 2017 M&A activity.
Merck: good long-term despite major setback
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze